Mayo Clinic and Thermo Fisher Scientific have launched Precure, LLC, a new company designed to identify the biological changes that occur before disease symptoms emerge.
The initiative will combine proteomic, genomic, and longitudinal clinical data in an effort to create one of the world’s largest biomedical datasets. Precure plans to generate molecular data from one million biospecimens and link those findings with clinical information collected over several years.
The goal is to give researchers a clearer view of how diseases develop from their earliest biological stages, potentially opening the door to earlier diagnosis, more targeted intervention, and new therapeutic strategies across areas including cancer, cardiometabolic disease, neurological disorders, and immune-mediated conditions.
Advanced artificial intelligence and large-scale data analytics will be used to identify patterns within the resulting datasets and translate them into potentially actionable biological insights.
Mayo Clinic will hold a majority stake in Precure, while Thermo Fisher will join as a founding partner and minority owner. Thermo Fisher will contribute its proteomics expertise and technologies, including the Olink Explore HT platform and Thermo Scientific Orbitrap Mass Spectrometry, as well as associated kits and reagents.
“By harnessing the full potential of multi-omics data, Precure, LLC aims to help us better understand disease before symptoms appear, accelerating discoveries that can lead to earlier diagnoses, more targeted treatments and better outcomes for patients,” said Gianrico Farrugia, president and CEO of Mayo Clinic, in a press release.
In the same press release, Thermo Fisher Chairman and CEO Marc Casper added that the collaboration could create “a step change” in how multi-omics data are generated and applied to human health, with the potential to support earlier disease detection and accelerate drug development.
Precure, LLC will complement Mayo Clinic’s existing Precure Research program, an investigator-led effort focused on understanding the transition from health to disease. The new company is intended to provide the infrastructure, scale, and external collaborations needed to generate population-level molecular datasets and support the development of diagnostics, therapeutics, and other healthcare technologies.
According to Mayo Clinic, any financial returns from the venture will be reinvested in its nonprofit missions of patient care, research, and education.
Source: Mayo Clinic.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
